Actavis to sell chlamydia drug Clamelle without prescription in the UK

Generic pharmaceutical company Actavis will launch its first ever over the counter (OTC) oral antibiotic in the UK.

Actavis, a generic drug manufacturer, has announced it will launch Clamelle Azithromycin at pharmacies across the UK – the first oral antibiotic available without a doctor’s prescription.

Clamelle is used for the treatment of people with chlamydia and for their sexual partners. The drug will be available in 500mg tablets and the dosage will be two tablets taken together as a single dose.

A pharmacy licence for Azithromycin was approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), after Actavis applied to switch Azithromycin tablets from prescription-only to pharmacy status.

Clamelle will be available for people 16 years and over if they have tested positive for the infection and have no symptoms, and for their sexual partners. Individuals will be able to obtain over the counter Clamelle from pharmacies following confirmation of diagnosis and a consultation with the pharmacist, and without a prescription from their GP or GUM clinic.

Sara Vincent, Manager of Actavis UK, said, “We are delighted to have been granted a pharmacy licence for Clamelle. This successful application is in line with Actavis UK’s programme of prescription-only to pharmacy switches, which is running in parallel with the expansion of the OTC brand portfolio through organic growth and strategic acquisitions.”

Actavis is currently developing training materials for UK pharmacies and finalising launch plans for Clamelle, as well as a chlamydia test kit.

Actavis is one of the world’s leading generic pharmaceutical companies specialising in the development, manufacture and sale of generic drugs. Based in Iceland, the company has operations in 40 countries and 11,000 employees.

More information on Clamelle and Actavis can be found at www.actavis.com

Contact:
Hjordis Arnadottir
Director – External Communications
Tel: (+354) 535 2300 / 840 7476
E-mail: harnadottir@actavis.com

Chris Bolwig

Recent Posts

Pipar\TBWA Named Advertising Agency of the Year for the Second Consecutive Year

Reykjavík, Iceland, 13.03.2025 - PiparTBWA has been named Advertising Agency of the Year for the…

3 weeks ago

QUIRKY CAMPERS UNVEILS DEDICATED GLASTONBURY 2025 CAMPERVAN FLEET

London, UK – March 12, 2025 – Quirky Campers, the UK's leading platform for handcrafted…

3 weeks ago

eXo Platform Unveils Version 7.0: A Game-Changer for the Digital Workplace

Paris, March 11, 2025 – eXo Platform, a leading open-source provider of intranet and digital…

3 weeks ago

Sasa Software Appoints Udi Doenyas as New Chairman of the Board

Tel Aviv, March 11, 2025 – Sasa Software, a global leader in advanced cybersecurity solutions…

3 weeks ago

Leaders, influencers, and individuals worldwide walk backwards to highlight the need to move forwards for women‘s rights.

Global Regression in Women's Rights Sparks UN Women National Committees’ 'March Forward' Campaign. Fri, Mar…

3 weeks ago

Savox Communications Initiates Cooperation Deal with a Northern European Customer for Advanced Audio and Intercom Command System

[Helsinki, Finland – March 7, 2025] – Savox Communications, a global leader in mission-critical communications…

4 weeks ago